Last reviewed · How we verify

NCT06749951: TreatSleepCHD

Cognitive Behavioural Therapy for Insomnia in Patients With Coronary Heart Disease

Recruiting now NA Last updated 9 January 2025
What this trial tests

NA trial testing Cognitive Behavioural Therapy for insomnia (CBT-I) in Insomnia Chronic in 76 participants. Currently enrolling.

Timeline
30 December 2024
Primary endpoint
15 June 2026
15 June 2026

Quick facts

Lead sponsorVestre Viken Hospital Trust
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment76
Start date30 December 2024
Primary completion15 June 2026
Estimated completion15 June 2026
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Vestre Viken Hospital Trust

Who can join

Adults 18 to 75, any sex, with Insomnia Chronic or Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Insomnia is prevalent (45%) in CHD patients and associated with significantly increased risk for recurrent cardiovascular events. Insomnia has recently been identified as the third most important risk factor for prognosis. However, very few insomnia patients are identified and receive treatment of insomnia today. CBT-I is the first-line treatment for insomnia, but studies on the effects in CHD patients are lacking. This project aims to document the effectiveness of Cognitive Behavioural therapy for insomnia (CBT-I) in an outpatient population with coronary heart disease (CHD). Furthermore, the biological and psychological mechanisms that may mediate the effects of the intervention will be identified. Finally, a health-economic simulation and a qualitative study of the participants experiences with CBT-I will be performed. This prospective, randomized, intervention study will continue until data have been collected for the primary outcome on 66 CHD outpatients with a diagnosis of insomnia assessed by Bergen Insomnia Scale (BIS). Participants will be randomised to a short, nurse-administered, CBT-I delivered in a group format or to sleep hygiene advice. The primary outcome will be remission from BIS-insomnia post-treatment and at 6-months follow-up. Secondary outcomes will be changes in insomnia severity, objective and subjective sleep parameters, daytime symptoms of insomnia, and quality of life. Exploratory outcomes include inflammation, cortisol, HbA1C, and cognitions/metacognitions. The project may document the effectiveness of CBT-I for a large patient-group with potentially favorable long-term effects on important clinical outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Insomnia Chronic

Currently open trials in the same condition.

Other Vestre Viken Hospital Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing